A PPAR-β/δ Agonist is Neuroprotective and Decreases Cognitive Impairment in a Rodent Model of Parkinson’s Disease

Author(s): Nihar R. Das, Rahul P. Gangwal, Mangesh V. Damre, Abhay T. Sangamwar, Shyam S. Sharma

Journal Name: Current Neurovascular Research

Volume 11 , Issue 2 , 2014

Become EABM
Become Reviewer
Call for Editor


Parkinson’s disease (PD) is associated with higher risk of cognitive impairment that may lead to memory loss, confusion, and decreased attention span. In this study, we have investigated the effect of GW0742, a PPAR-β/δ agonist in rat model of cognitive impairment associated with PD. Bilateral intranigral administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) (100 µg/1 µl/side) produced significant cognitive dysfunctions. PPAR-β/δ agonist GW0742 at a dose of 30 and 100 µg/kg showed significant improvement in cognitive impairments caused by MPTP in rat model of PD as evident from passive avoidance and Morris water maze test. MPTP-induced massive oxidative damage and DNA fragmentation was ameliorated by GW0742 treatment as observed after MDA and GSH estimation and TUNEL assay. Tyrosine hydroxylase positive neurons were decreased by 25% of normal control in MPTP group and GW0742 treatment restored tyrosine hydroxylase levels showing neuroprotective nature. Further, we performed physiologically based pharmacokinetic (PBPK) modeling study using GastroPlus to characterize the kinetics of GW0742 in the brain. The predicted amounts of GW0742 in brain suggest that it has the ability to cross the blood brain barrier. This study implicates the involvement of PPAR-β/δ in PD induced cognitive impairment.

Keywords: GastroPlus, GW0742, MPTP, parkinson’s disease, PBPK modeling, PPAR beta.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 07 May, 2014
Page: [114 - 124]
Pages: 11
DOI: 10.2174/1567202611666140318114037
Price: $65

Article Metrics

PDF: 33